GSK4527226 in Early Alzheimer's Disease

GSK4527226 (anti-CD33/Siglec-3 mAb, ex-AL-002 from Alector) targets microglial modulation, a mechanism with repeated Phase 2 failures in AD (INVOKE-2 for AL-002 missed CDR-SB in late 2024). Phase 2 AD CDR-SB readouts over 52-76w have low base rate (~20-25%). Active-not-recruiting supports on-time readout, but mechanism and prior-class signal argue against hitting CDR-SB significance vs placebo.

Early Alzheimer’s Phase 2 trials have a high failure rate, and CDR-SB is a clinically meaningful but difficult endpoint to move. This study tests dose 1 vs placebo on a long readout, with no supportive prior efficacy signal provided here. Good design and a large sponsor help execution, but intrinsic odds of primary success still look low.

Novel anti-sortilin mAb elevates PGRN with Phase 1 target engagement (dose-dependent CSF PGRN rise) and genetic rationale from SORT1/PGRN links to neurodegeneration. No prior AD efficacy data however. Appropriate early AD population and validated CDR-SB primary (Dose 1 vs placebo, repeated measures at 52/64/76w) but Alzheimer's Phase 2 success rates low for non-amyloid mechanisms. n=367, DBPC design, enrollment completed ahead of schedule lowers operational/disclosure risk.

AL101 elevates progranulin via sortilin blockade, the exact mechanism of Alector's AL001. In Oct 2025, AL001 failed its Phase 3 in FTD-GRN, showing zero clinical benefit in a disease caused directly by progranulin deficiency. Consequently, the biological rationale for AD is severely compromised. Furthermore, this 282-patient AD trial is historically underpowered for a CDR-SB primary endpoint.

Phase 2 Alzheimer's trials have high historical failure rate. Primary endpoint uses CDR-SB, a standard but demanding measure. Sponsor GSK is experienced, but target population is heterogeneous (MCI and mild dementia). No prior efficacy data disclosed; intrinsic odds are low.

Phase 2 Alzheimer's trials face high historical attrition. While CDR-SB is a clinically accepted endpoint, demonstrating a statistically significant slowing of progression in early AD is difficult. The active-not-recruiting status suggests enrollment is complete, but without interim data, the probability of success remains low relative to market expectations.

Phase 2 trial with moderate sample size, primary endpoint based on change from baseline in CDR-SB score, and a relatively short duration.

GSK4527226 is an early-stage anti-amyloid antibody with no prior Phase 2 data disclosed. Alzheimer's Phase 2 trials historically show ~15-25% success rates for novel mechanisms. CDR-SB endpoint at 76 weeks requires sustained clinical benefit. GSK's track record in neurodegeneration is weak (failed adecanumab partnership). Active Not Recruiting status with 162 days to completion suggests enrollment complete but no interim efficacy signals leaked—neutral to slightly negative. Two dose levels increase power but no adaptive design mentioned.

Phase 2 Alzheimer's trial with CDR-SB endpoint faces high failure risk. Historical Alzheimer's Phase 2 success rates are low (~20-30%). No prior efficacy signals disclosed. GSK4527226 is an early-stage program with limited public data. The multi-dose design adds complexity.